weight watchers glp 1 WeightWatchers - WeightWatchers added a
Description
doi:10.1016/S2213-8587(25)00092-0
Clinical outcomes with compounded semaglutide mirror those of brand-name formulations when sourced from licensed 503A compounding pharmacies
November 2025: FDA approved expanded Zepbound (tirzepatide) indication for moderate-to-severe obstructive sleep apnea in adults with obesity, following SURMOUNT-OSA trial data showing 62.8% reduction in apnea-hypopnea index the first drug approval for sleep apnea treatment
69:2414-2426 [PMC free article: PMC6594101] [PubMed: 30341767] 334
GLP-1RAs and co-agonists have shown promising outcomes in the clinical management of MASLD
